Zobrazeno 1 - 10
of 246
pro vyhledávání: '"Luwen Shi"'
Publikováno v:
BMC Geriatrics, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Potentially inappropriate medications (PIMs) are common among older adults with cancer, but their association with overall survival (OS) among non-small cell lung cancer (NSCLC) patients remains unclear. This study aimed to invest
Externí odkaz:
https://doaj.org/article/e5a8897f129941e5b18505025f449962
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 46, Iss , Pp 101077- (2024)
Summary: Background: Health-related quality of life (HRQoL), along with overall survival (OS), is a critical study endpoint for measuring the clinical benefits of cancer drugs. Previous studies have examined the OS benefit of new cancer drugs approve
Externí odkaz:
https://doaj.org/article/c48dde7c599044479ea9778375617af4
Autor:
Zhuo Ma, Huangqianyu Li, Yi Zhang, Lan Zhang, Guo Huang, Yichen Zhang, Luwen Shi, Wei Liu, Zhuoling An, Xiaodong Guan
Publikováno v:
EClinicalMedicine, Vol 71, Iss , Pp 102561- (2024)
Summary: Background: Aggressive care near patients’ end-of-life (EOL) entails limited therapeutic values, high costs, and compromised quality of life (QoL). In this study, we aimed to estimate the global prevalence of aggressive care in patients wi
Externí odkaz:
https://doaj.org/article/8b5da6ce1b664592b22eccf8b3414be5
Autor:
Xiaoyan Nie, Ruilin Wang, Guangkai Liang, Xinyi Zhang, Ningjia Tang, Yuchun Cai, Congxiao Han, Yuxuan Zhao, Tong Jia, Fang Zhang, Sheng Han, Xiaodong Guan, Luwen Shi, Christine Lu
Publikováno v:
International Journal of Health Policy and Management, Vol 12, Iss Issue 1, Pp 1-10 (2023)
Background A prescribing monitoring policy (PMP) was implemented in November 2015 in Anhui province, China, the first province to pilot this policy to manage the use and costs of select drugs based on their large prescription volumes and/or costs in
Externí odkaz:
https://doaj.org/article/6468bb7713b4445a9e150b3957d72ae7
Autor:
Mengyuan Fu, Can Li, Zinan Zhao, Kexin Ling, Zhiwen Gong, Huangqianyu Li, Ting Li, Jianchun Li, Weihang Cao, Xin Hu, Luwen Shi, Pengfei Jin, Xiaodong Guan
Publikováno v:
BMC Geriatrics, Vol 23, Iss 1, Pp 1-9 (2023)
Abstract Background With the rapid aging trend of China's population, the issue of drug rational use in older adults has become more and more prominent. Parkinson’s disease (PD) is the one of the most common age-related neurodegenerative disorders.
Externí odkaz:
https://doaj.org/article/c0ed1a553f7249d88adc6f59dd527d3e
Autor:
Yuxuan Wei, Yichen Zhang, Ziyue Xu, Guoan Wang, Yue Zhou, Huangqianyu Li, Luwen Shi, Huseyin Naci, Anita K. Wagner, Xiaodong Guan
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 45, Iss , Pp 101055- (2024)
Summary: Background: Perceived delays in cancer drug approvals have been a major concern for policymakers in China. Policies have been implemented to accelerate the launch of new cancer drugs and indications. This study aimed to assess similarities a
Externí odkaz:
https://doaj.org/article/71807fe6a9d94b84b62c2e5db2318c2f
Autor:
Yichen Zhang, Dingyi Chen, Siyuan Cheng, Zhizhou Liang, Lu Yang, Qian Li, Lin Bai, Huangqianyu Li, Wei Liu, Luwen Shi, Xiaodong Guan
Publikováno v:
PLoS Medicine, Vol 20, Iss 12 (2023)
Externí odkaz:
https://doaj.org/article/68202da42e4848ad8cb66da788c77b94
Autor:
Xiaodong Guan, Luwen Shi, Sheng Han, Zixuan He, Dingyi Chen, Huangqianyu Li, Xianqin Huang, Guoan Wang, Yuezhen Zhu
Publikováno v:
BMJ Global Health, Vol 8, Iss 11 (2023)
Background China’s National Reimbursement Drug List (NRDL) has become the primary route for drug reimbursement in China. More recently, the authority has made pharmacoeconomic evaluation an integral part of the application for NRDL inclusion. The u
Externí odkaz:
https://doaj.org/article/af85cbef63ad4ea89b65f8162b5aef44
Autor:
Mengyuan Fu, Zhiwen Gong, Can Li, Kexin Ling, Yuezhen Zhu, Huangqianyu Li, Luwen Shi, Xiaodong Guan
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 40, Iss , Pp 100880- (2023)
Summary: Background: The appropriateness of antibiotic use for acute respiratory infections (ARIs) in Chinese primary healthcare facilities (PHFs) remained uncertain. We aimed to evaluate to what degree antibiotic prescribing for ARIs were aligned wi
Externí odkaz:
https://doaj.org/article/1217548db9964e9cb455f4fd29e7e503
Autor:
Huseyin Naci, Xiaodong Guan, Luwen Shi, Anita Katharina Wagner, Yue Zhou, Dingyi Chen, Lin Bai
Publikováno v:
BMJ Global Health, Vol 8, Iss 9 (2023)
Introduction We examined overall survival (OS) benefits for targeted cancer drugs recommended for List of Essential Medicines (EMLs) since 2015. We assessed consistency of decisions in 2019 and 2021 with more specific criteria: OS benefit >4 months a
Externí odkaz:
https://doaj.org/article/8594acaf1867473aa53a8ac148772173